|Last Price$2.70||Day Change (%)6.30%|
|Open Price$2.49||Day Change ($)0.16|
|Day Range2.54–2.70||52-Week Range1.26–4.55|
As of Mon 3/30/2015 5:00:00 PM | USD
The lack of early success in its lead drug's cancer trial scares the market, but we see a buying opportunity.
Research and Markets: Cabozantinib - Comprehensive Patent Search Portal
Lack of competitive advantages may mean these companies aren't the bargains they seem to be.
We see opportunity as fleeing investors trigger an irrational sell-off.
Morningstar analysts see pharmaceuticals as 2010's hot zone for mergers and acquisitions.
The five biotech ETFs have very different portfolios with markedly different performance.